Kanilad (Lacosamide)

Kanilad, a sodium channel blocker, is employed in the management of seizure disorders.

• Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens.
• Focal epilepsy: Helps achieve better overall seizure control in patients with focal seizure types.
• Epilepsy (adjunctive therapy): Contributes to improved seizure management as part of a comprehensive treatment plan.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and decreasing repetitive neuronal firing. This modulation reduces the likelihood of seizure initiation and propagation without significantly affecting normal neuronal activity.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: A sensation of light‑headedness or unsteadiness.
• Headache: Mild to moderate pain in the head region.
• Nausea: Feeling of stomach upset or urge to vomit.
• Fatigue: Unusual tiredness or lack of energy.
• Blurred vision: Temporary visual disturbances.
• Diplopia: Double vision.

Serious or Rare Side Effects

• Suicidal thoughts or behavior: Emergence of depressive symptoms or suicidal ideation.
• Severe skin reactions: Including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmias: Irregular heart rhythms, especially in patients with pre‑existing conduction disorders.
• Respiratory depression: Marked slowing of breathing.
• Anaphylaxis: Acute allergic reaction with potential airway compromise.
• Liver injury: Elevated liver enzymes or hepatitis.

When prescribing or dispensing Kanilad, consider the following safety measures.

• Renal impairment: Assess kidney function and adjust therapy if necessary.
• Hepatic impairment: Monitor liver enzymes regularly.
• Concomitant antiepileptics: Observe for increased central nervous system side effects.
• Cardiac conduction disorders: Use with caution in patients with known arrhythmias.
• Pregnancy: Potential risks are unknown; discuss benefits and risks with a healthcare professional.
• Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): May lower lacosamide plasma levels.
• Other sodium channel blockers (e.g., lamotrigine, phenytoin): May increase neurotoxicity.
• QT‑prolonging agents (e.g., quinidine, erythromycin): Heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: May reduce contraceptive effectiveness; consider alternative methods.
• Combination with other antiepileptics: May increase dizziness or somnolence.
• Alcohol: Can enhance central nervous system depression and impair coordination.